Last updated: February 19, 2026
This report analyzes Canadian patent CA2939990, covering its scope, claims, and the broader patent landscape relevant to its technological domain. The patent, filed by Bayer Pharma AG, pertains to substituted azabicyclo[3.2.1]octane derivatives and their use in treating various medical conditions.
What is the Core Technology Protected by CA2939990?
Patent CA2939990 protects novel substituted azabicyclo[3.2.1]octane derivatives. These compounds are characterized by a specific chemical structure that confers activity in modulating biological targets relevant to disease. The patent’s claims encompass not only the chemical compounds themselves but also pharmaceutical compositions containing these compounds and their methods of use for treating specific medical indications.
What are the Key Claims and Their Breadth?
The claims of CA2939990 define the exclusive rights granted. They are structured to cover:
- Compound Claims: These claims define the specific chemical structures of the azabicyclo[3.2.1]octane derivatives. Claim 1, the primary compound claim, is broad in its definition of substituents and the core bicyclic structure, allowing for a range of related molecules. Subsequent claims further define specific embodiments and preferred ranges of substituents. For example, claim 2 recites a genus of compounds where R1, R2, R3, R4, and R5 are defined within specific ranges of chemical groups and atoms.
- Composition Claims: These claims cover pharmaceutical formulations that include at least one of the claimed compounds as an active pharmaceutical ingredient (API), along with pharmaceutically acceptable carriers, diluents, or excipients. Claim 11, for instance, describes a pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- Method of Use Claims: These claims outline the therapeutic applications of the claimed compounds. They specify methods for treating various diseases by administering a therapeutically effective amount of a compound of the patent. The indications are generally related to conditions affecting the central nervous system and metabolic disorders. Claim 16 broadly claims a method of treating a disease selected from a list that includes diabetes mellitus, obesity, and neurological disorders.
The breadth of the claims is a critical factor for competitive analysis. The generalized definitions of substituents in early claims allow for a wide array of potential chemical variants. This broad scope can impact the freedom to operate for competitors developing similar therapeutic agents.
What are the Specific Therapeutic Indications Claimed?
CA2939990 claims methods for treating a range of medical conditions. These indications are based on the pharmacological activity of the protected compounds. Specific indications listed in the patent include, but are not limited to:
- Diabetes Mellitus (Type 1 and Type 2)
- Obesity
- Metabolic Syndrome
- Neurological Disorders such as Alzheimer's disease and Parkinson's disease
- Inflammatory Conditions
The patent establishes a link between the azabicyclo[3.2.1]octane derivatives and their ability to modulate specific biological pathways relevant to these diseases.
What is the Priority Date and Term of CA2939990?
Understanding the patent's timeline is crucial for assessing its current relevance and remaining protection period.
- Filing Date: August 28, 2015
- Priority Date: August 29, 2014 (from PCT application EP2014068051)
- Grant Date: June 19, 2018
- Expiry Date: August 29, 2034 (20 years from the priority date)
The patent is currently in force, with protection extending for several more years.
What is the Status of CA2939990?
CA2939990 is granted and in force. This means the patent claims are legally valid in Canada, and infringement could lead to legal action.
What is the Technological Field of CA2939990?
The patent falls within the intersection of medicinal chemistry and pharmacology, specifically focusing on novel small molecule therapeutics. The core technology involves:
- Organic Synthesis: Development of synthetic routes to produce the novel azabicyclo[3.2.1]octane derivatives.
- Medicinal Chemistry: Design and optimization of chemical structures for biological activity and favorable pharmacokinetic properties.
- Pharmacology: In vitro and in vivo testing to demonstrate efficacy and mechanism of action against specific disease targets.
- Drug Development: Formulation and preclinical evaluation for therapeutic potential.
The compounds are generally described as modulators of specific protein targets involved in metabolic regulation and neurological pathways.
What is the Competitive Landscape for CA2939990?
The competitive landscape for CA2939990 involves other companies and research institutions developing therapeutics for the same or similar indications. Key areas of competition include:
- Other Modulators of Similar Targets: Competitors may be developing drugs that target the same biological pathways as the compounds claimed in CA2939990, but with different chemical scaffolds.
- Alternative Therapeutic Modalities: Companies may be pursuing different drug classes (e.g., biologics, gene therapies) or entirely different mechanisms of action to treat the same diseases.
- Evergreening Strategies: Pharmaceutical companies often file follow-on patents for new formulations, delivery methods, or specific patient populations of existing drugs to extend market exclusivity. While CA2939990 is an original compound patent, its lifecycle will be influenced by these broader industry strategies.
- Generic Competition: Once CA2939990 expires, generic manufacturers will be able to produce and market biosimilar versions of any approved drugs based on these patents, provided other regulatory hurdles are cleared.
Specific competitors to monitor would include pharmaceutical companies active in diabetes, obesity, and neuroscience research. Examples of companies with significant R&D in these areas include Novo Nordisk, Eli Lilly and Company, Pfizer, and Merck & Co.
Are There Any Related Patents or Patent Families?
Bayer Pharma AG, the assignee of CA2939990, has a substantial patent portfolio in related therapeutic areas. A search of patent databases for Bayer and its subsidiaries would reveal related patents. The international patent family associated with CA2939990 indicates filings in multiple jurisdictions, suggesting a global commercialization strategy. Analyzing this patent family is essential to understand the worldwide protection for this technology. For instance, PCT/EP2014/068051 is the parent application for this patent family, with corresponding patents likely filed in the US, Europe, Japan, and other key markets.
What are the Implications for R&D and Investment Decisions?
The existence and scope of CA2939990 have direct implications:
- For R&D: Companies developing compounds targeting the same biological pathways or indications claimed in CA2939990 must conduct thorough freedom-to-operate (FTO) analyses. This includes scrutinizing the exact definitions in the claims and identifying any potential for infringement. The broad nature of some claims may necessitate the design of compounds that clearly fall outside the patent's scope.
- For Investment: Investors must consider the patent's remaining term and the competitive landscape. The strong patent protection offered by CA2939990 can create a period of market exclusivity for an approved drug, potentially leading to significant revenue. However, the cost and timeline of drug development, regulatory approval, and potential litigation are also critical factors. The patent's expiration date of August 29, 2034, provides a clear horizon for market exclusivity.
Key Takeaways
- Patent CA2939990 protects novel substituted azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions containing them, and methods for their use in treating diabetes, obesity, metabolic disorders, and neurological conditions.
- The patent has a broad scope, with compound claims defining a genus of molecules and method claims covering multiple therapeutic indications.
- CA2939990 is granted and in force in Canada until August 29, 2034, providing a significant period of market exclusivity for any approved products derived from this patent.
- The competitive landscape includes other drug developers targeting similar disease pathways or employing alternative therapeutic modalities.
- Thorough freedom-to-operate assessments are crucial for entities developing R&D in this therapeutic space to avoid infringement.
Frequently Asked Questions
-
Can another company develop a similar drug in Canada while CA2939990 is active?
A competitor can develop a similar drug if its chemical structure and/or method of use fall outside the specific claims of CA2939990. A detailed freedom-to-operate analysis is required to determine this.
-
What happens if a competitor's drug is approved before CA2939990 expires?
If a competitor's drug is approved and it infringes on the claims of CA2939990, the patent holder (Bayer Pharma AG) can pursue legal action for patent infringement.
-
Does CA2939990 cover all drugs for diabetes or obesity?
No, CA2939990 specifically covers compounds with the azabicyclo[3.2.1]octane core structure and their methods of use for treating these conditions. It does not cover all possible drugs for diabetes or obesity.
-
What is the significance of the priority date?
The priority date establishes the earliest date for determining the novelty and inventive step of the invention. It is critical for assessing patentability and for determining the patent's term.
-
Are there any known challenges or oppositions filed against CA2939990?
A review of the Canadian Intellectual Property Office (CIPO) database and patent litigation records would be necessary to determine if any oppositions or legal challenges have been filed against CA2939990. Such information is not publicly accessible through a basic patent number search.
Citations
[1] Bayer Pharma AG. (2018). Canadian Patent CA2939990. Canadian Intellectual Property Office.
